Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ondansetron + rabeprazole
- Development stage
- Unknown
- Lead developer
- Mits Healthcare
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Rabimits-OD is a fixed-dose combination pharmaceutical product developed by Mits Healthcare, containing the proton pump inhibitor (PPI) **rabeprazole** and the antiemetic **ondansetron**. Rabeprazole works by irreversibly inhibiting the H+/K+ ATPase enzyme system (the gastric proton pump) in the parietal cells of the stomach, thereby suppressing both basal and stimulated gastric acid secretion. Ondansetron is a selective serotonin 5-HT3 receptor antagonist that prevents nausea and vomiting by blocking serotonin receptors in the chemoreceptor trigger zone (CTZ) and on peripheral vagal nerve terminals. This combination is primarily indicated for the treatment of gastroesophageal reflux disease (GERD), peptic ulcers, and acid-related dyspepsia, particularly when these conditions are accompanied by nausea or vomiting.
- Brand names
- Rabimits-OD
- Other names
- Rabeprazole and Ondansetron Tablets
02
Targets
CYP3A4 (Cytochrome P450 3A4)ATP4A (Potassium–transporting ATPase alpha chain 1)HTR3A (5-hydroxytryptamine receptor 3A)
Beyond the preview
Go deeper on ondansetron + rabeprazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ondansetron + rabeprazole.